Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Appendiceal Neoplasms
/ pathology
Appendix
Cisplatin
Combined Modality Therapy
Cytoreduction Surgical Procedures
/ methods
Disease-Free Survival
Feasibility Studies
Female
Humans
Hyperthermia, Induced
/ methods
Male
Middle Aged
Mitomycin
/ administration & dosage
Peritoneal Neoplasms
/ mortality
Pseudomyxoma Peritonei
/ mortality
Survival Rate
Treatment Outcome
Appendiceal neoplasms
Cytoreductive surgery
HIPEC
Hyperthermic intraperitoneal chemotherapy
PMP
Pseudomyxoma peritonei
Journal
Updates in surgery
ISSN: 2038-3312
Titre abrégé: Updates Surg
Pays: Italy
ID NLM: 101539818
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
07
02
2020
accepted:
02
05
2020
pubmed:
16
5
2020
medline:
31
12
2020
entrez:
16
5
2020
Statut:
ppublish
Résumé
Pseudomyxoma peritonei (PMP) is a rare condition characterized by the intraperitoneal accumulation of mucus derived mostly by appendiceal mucinous neoplasm. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) can offer a favourable overall survival. In this study, we report a single-institute outcomes following CRS and HIPEC in patients with this condition. This is a review of prospectively collected data from 32 patients (11 men and 21 women) affected by PMP of appendiceal origin who underwent CRS and HIPEC from 2008 to 2016 in our Surgical Unit of General and Esophagogastric Surgery. The median age of the patients was 53 years (range 25-77 years). After CRS, all patients underwent HIPEC (mytomicin C 3.3 mg/m
Identifiants
pubmed: 32410159
doi: 10.1007/s13304-020-00788-5
pii: 10.1007/s13304-020-00788-5
doi:
Substances chimiques
Mitomycin
50SG953SK6
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1207-1212Références
Delhorme J-B, Severac F, Averous G, Glehen O, Passot G, Bakrin N, Marchal F, Pocard M, Lo Dico R, Eveno C, Carrere S, Sgarbura O, Quenet F, Ferron G, Goéré D, Brigand C, French National Network of Peritoneal Surface Malignancies (2018) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin. Br J Surg 105:668–676. https://doi.org/10.1002/bjs.10716
doi: 10.1002/bjs.10716
pubmed: 29412465
Sugarbaker PH (2006) New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7:69–76. https://doi.org/10.1016/S1470-2045(05)70539-8
doi: 10.1016/S1470-2045(05)70539-8
pubmed: 16389186
Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM (1995) Disseminated peritoneal adenomucinosis and peritoneal mucinous adenomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Am J Surg Pathol 19:1390–1408. https://doi.org/10.1097/00000478-199512000-00006
doi: 10.1097/00000478-199512000-00006
pubmed: 7503361
Mehta SS, Bhatt A, Glehen O (2016) Cytoreductive surgery and peritonectomy procedures. Indian J Surg Oncol 7:139–151. https://doi.org/10.1007/s13193-016-0505-5
doi: 10.1007/s13193-016-0505-5
pubmed: 27065704
pmcid: 4818624
Halkia E, Tsochrinis A, Vassiliadou DT, Pavlakou A, Vaxevanidou A, Datsis A, Efstathiou E, Spiliotis J (2015) Peritoneal carcinomatosis: Intraoperative parameters in open (Coliseum) versus closed abdomen HIPEC. Int J Surg Oncol 2015:610597. https://doi.org/10.1155/2015/610597
doi: 10.1155/2015/610597
pubmed: 25785194
pmcid: 4345051
Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Cancer treatment and research, vol 82. Springer, Boston, pp 359–374. https://doi.org/10.1007/978-1-4613-1247-5_23
doi: 10.1007/978-1-4613-1247-5_23
Sugarbaker PH, Chang D (1999) Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 6:727–731. https://doi.org/10.1007/s10434-999-0727-7
doi: 10.1007/s10434-999-0727-7
Yan TD, Links M, Xu ZY, Kam PC, Glenn D, Morris DL (2006) Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg 93:1270–1276. https://doi.org/10.1002/bjs.5427
doi: 10.1002/bjs.5427
pubmed: 16838392
Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA (2007) Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg 245:104–109. https://doi.org/10.1097/01.sla.0000231705.40081.1a
doi: 10.1097/01.sla.0000231705.40081.1a
pubmed: 17197972
pmcid: 1867935
Chua TC, Yan TD, Smigielski ME, Zhu KJ, Ng KM, Zhao J, Morris DL (2009) Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol 16:1903–1911. https://doi.org/10.1245/s10434-009-0341-8
doi: 10.1245/s10434-009-0341-8
pubmed: 19387742
Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O, Association Française de Chirurgie (2010) Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 36:456–462. https://doi.org/10.1016/j.ejso.2010.01.006
doi: 10.1016/j.ejso.2010.01.006
pubmed: 20227231
Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30:2449–2456. https://doi.org/10.1200/JCO.2011.39.7166
doi: 10.1200/JCO.2011.39.7166
pubmed: 22614976
Schneider MA, Eshmuminov D, Lehmann K (2017) Major postoperative complications are a risk factor for impaired survival after CRS/HIPEC. Ann Surg Oncol 24:2224–2232. https://doi.org/10.1245/s10434-017-5821-7
doi: 10.1245/s10434-017-5821-7
pubmed: 28265776
Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, González-Moreno S, Taflampas P, Chapman S, Moran BJ; Peritoneal Surface Oncology Group International (2016) A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the peritoneal surface oncology group international (PSOGI) modified delphi process. Am J Surg Pathol 40:14–26. https://doi.org/10.1097/PAS.0000000000000535
doi: 10.1097/PAS.0000000000000535
Shetty S, Natarajan B, Thomas P, Govindarajan V, Sharma P, Loggie B (2013) Proposed classification of pseudomyxoma peritonei: influence of signet ring cells on survival. Am Surg 79:1171–1176
doi: 10.1177/000313481307901120
Munoz-Zuluaga C, Sardi A, King MC, Nieroda C, Sittig M, MacDonald R, Gushchin V (2018) Outcomes in peritoneal dissemination from signet ring cell carcinoma of the appendix treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 26:473–481. https://doi.org/10.1245/s10434-018-7007-3
doi: 10.1245/s10434-018-7007-3
pubmed: 30523470
Piso P, Nedelcut SD, Rau B, Königsrainer A, Glockzin G, Ströhlein MA, Hörbelt R, Pelz J (2019) Morbidity and mortality following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: data from the DGAV StuDoQ Registry with 2149 consecutive patients. Ann Surg Oncol 26:148–154. https://doi.org/10.1245/s10434-018-6992-6
doi: 10.1245/s10434-018-6992-6
pubmed: 30456672
Raspé C, Flöther L, Schneider R, Bucher M, Piso P (2017) Best practice for perioperative management of patients with cytoreductive surgery and HIPEC. Eur J Surg Oncol 43:1013–1027. https://doi.org/10.1016/j.ejso.2016.09.008
doi: 10.1016/j.ejso.2016.09.008
pubmed: 27727026
Tempfer CB, Solass W, Buerkle B, Reymond MA (2014) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei: a case report. Gynecol Oncol Rep 18(10):32–35. https://doi.org/10.1016/j.gore.2014.10.001
doi: 10.1016/j.gore.2014.10.001